Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.
Masquelier B, Tamalet C, Montès B, Descamps D, Peytavin G, Bocket L, Wirden M, Izopet J, Schneider V, Ferré V, Ruffault A, Palmer P, Trylesinski A, Miller M, Brun-Vézinet F, Costagliola D; ANRS AC11 Resistance study group. Masquelier B, et al. Among authors: ferre v. Antivir Ther. 2004 Jun;9(3):315-23. Antivir Ther. 2004. PMID: 15259894 Clinical Trial.
R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.
Masquelier B, Droz C, Dary M, Perronne C, Ferré V, Spire B, Descamps D, Raffi F, Brun-Vézinet F, Chêne G; APROCO/COPILOTE Study Group. Masquelier B, et al. Among authors: ferre v. Antimicrob Agents Chemother. 2003 Nov;47(11):3623-6. doi: 10.1128/AAC.47.11.3623-3626.2003. Antimicrob Agents Chemother. 2003. PMID: 14576131 Free PMC article. Clinical Trial.
HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.
Descamps D, Assoumou L, Masquelier B, Marcelin AG, Saidi S, Tamalet C, Cottalorda J, Plantier JC, Montes B, Izopet J, Peytavin G, Yerly S, Schneider V, Delaugerre C, Ferré V, Ruffault A, Pallier C, Morand-Joubert L, Chaix ML, Calvez V, Brun-Vézinet F, Costagliola D; ANRS AC-11 Resistance Study Group. Descamps D, et al. Among authors: ferre v. J Antimicrob Chemother. 2008 Sep;62(3):451-5. doi: 10.1093/jac/dkn225. Epub 2008 Jun 13. J Antimicrob Chemother. 2008. PMID: 18552344
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
Recordon-Pinson P, Soulié C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Macé M, Ferré V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B; ANRS AC11 Resistance Study Group. Recordon-Pinson P, et al. Among authors: ferre v. Antimicrob Agents Chemother. 2010 Aug;54(8):3335-40. doi: 10.1128/AAC.00148-10. Epub 2010 Jun 7. Antimicrob Agents Chemother. 2010. PMID: 20530226 Free PMC article.
Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters.
Dailly E, Rodallec A, Allavena C, Deslandes G, Garnier E, Billaud E, Ferré V, Reliquet V, Bouquié R, Raffi F, Jolliet P. Dailly E, et al. Among authors: ferre v. Fundam Clin Pharmacol. 2012 Aug;26(4):538-42. doi: 10.1111/j.1472-8206.2011.00949.x. Epub 2011 May 5. Fundam Clin Pharmacol. 2012. PMID: 21545648
Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.
Lambert-Niclot S, Masquelier B, Cohen Codar I, Soulie C, Delaugerre C, Morand-Joubert L, Charpentier C, Ferre V, Plantier JC, Montes B, Carret S, Perrot V, Peytavin G, Costagliola D, Calvez V, Marcelin AG; EOLE Study Group. Lambert-Niclot S, et al. Among authors: ferre v. J Antimicrob Chemother. 2012 Oct;67(10):2487-93. doi: 10.1093/jac/dks226. Epub 2012 Jun 25. J Antimicrob Chemother. 2012. PMID: 22733652
A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.
Marcelin AG, Delaugerre C, Beaudoux C, Descamps D, Morand-Joubert L, Amiel C, Schneider V, Ferre V, Izopet J, Si-Mohamed A, Maillard A, Henquell C, Desbois D, Lazrek M, Signori-Schmuck A, Rogez S, Yerly S, Trabaud MA, Plantier JC, Fourati S, Houssaini A, Masquelier B, Calvez V, Flandre P; ANRS AC11 Resistance Group. Marcelin AG, et al. Among authors: ferre v. Int J Antimicrob Agents. 2013 Jul;42(1):42-7. doi: 10.1016/j.ijantimicag.2013.02.016. Epub 2013 Apr 4. Int J Antimicrob Agents. 2013. PMID: 23562640
Algorithm-based prediction of HIV-1 subtype D coreceptor use.
Dina J, Raymond S, Maillard A, Le Guillou-Guillemette H, Rodalec A, Beby-Defaux A, Giraudeau G, Vallet S, Mourez T, Payan C, Vabret A, Ruffault A, Ferre V, Izopet J, Plantier JC. Dina J, et al. Among authors: ferre v. J Clin Microbiol. 2013 Sep;51(9):3087-9. doi: 10.1128/JCM.00798-13. Epub 2013 Jun 26. J Clin Microbiol. 2013. PMID: 23804380 Free PMC article.
177 results